Ongoing, recruitingHuman Pharmacology (Phase I)- OtherInterventional

A clinical study of MK-2420 in healthy men (MK-2420-003)

This research study, called MK-2420-003, is trying out a new medicine, MK-2420. It's a very early-stage study, meaning it's one of the first times this medicine is being given to people. The main aim is to understand how MK-2420 behaves in the healthy human body and to check if it's safe. It's focusing on men aged 18 and over. While this specific study is in healthy participants, the medicine is being developed with the hope of eventually helping people with conditions like rheumatoid arthritis. Taking part could help scientists learn more about new treatments for some long-term illnesses.

At a glance

Status

Ongoing, recruiting

Phase

Human Pharmacology (Phase I)- Other

Sponsor

Merck Sharp & Dohme LLC

Enrolment target

Start

29 Nov 2024

Rheumatoid arthritis

What is this study about?

This study is named MK-2420-003 and it's all about understanding a new medicine called MK-2420. Think of it like taking a brand new car for a test drive to see how it runs. Researchers want to see how this medicine acts inside the human body. They'll be looking at things like how much of it gets into your system, how long it stays there, and how your body reacts to it. This early testing is really important to make sure a new medicine is safe before it can be studied in people who are unwell.

This particular study is in its very first stage of human testing, often called Phase I. This means it's one of the first times this medicine is being given to people. Because it's so early, the study is focused on healthy volunteers, not people who are ill. This allows researchers to get a clear picture of how the medicine works without other health problems complicating the results. It's also a smaller study compared to later stages.

The bigger picture is that this medicine, MK-2420, is being developed with the aim of potentially treating conditions like rheumatoid arthritis in the future. Rheumatoid arthritis is a long-term condition that causes pain, swelling, and stiffness in the joints. By understanding how MK-2420 works safely in healthy men, scientists can then decide if it's promising enough to be tested in people living with these conditions, hopefully leading to new and better treatments down the line.

Key takeaways

This is a study of a new medicine, MK-2420, in healthy adult men.
It's a very early-stage study to understand safety and how the medicine works in the body.
The medicine aims to help with conditions like rheumatoid arthritis in the future.
Participation involves clinic visits, taking the medicine, and close monitoring.
You can stop participating at any time if you change your mind.

Who may be eligible?

This study is specifically looking for healthy men to take part. To join, you must be at least 18 years old – there's no upper age limit, as long as you're in good general health.

The most important thing is that you should be considered healthy by the study doctors. This means you do not have any significant ongoing medical conditions, especially those that might affect how your body reacts to the new medicine. However, the study information provided is very brief, so there would be many more health requirements and checks to make sure you are suitable and safe to participate.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you a man?
Are you 18 years old or older?
Are you generally healthy with no major ongoing medical conditions?
Are you able to commit to several clinic visits?

Answer every question to see your result.

What does participation involve?

If you decide to take part, you would likely need to visit the study clinic several times. During these visits, doctors and nurses would perform various checks to ensure you are healthy enough for the study. This might include physical exams, blood tests, urine tests, and checking your heart. You would then be given the study medicine, MK-2420, often in different doses and at different times.

After taking the medicine, you would be closely monitored. This could involve staying at the clinic for a period, having more blood samples taken, and answering questions about how you feel. The total time you'd be involved in the study, including all your visits and follow-ups, would be explained to you in detail before you agree to participate.

Potential risks and benefits

Taking part in any medical study carries potential benefits and risks. A potential benefit could be contributing to medical science, which might lead to new treatments for conditions like rheumatoid arthritis in the future. However, because this is a very new medicine, there might be unknown side effects or reactions. You would be carefully monitored for any problems, but there's a chance you could experience discomfort or unexpected effects from the medicine. It's important to remember you can always withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Belgium

Common questions

What is MK-2420?

MK-2420 is a new medicine being developed that might help people with conditions like rheumatoid arthritis in the future.

Why are healthy men involved in this study?

Because it's a very early-stage study, researchers test the medicine in healthy volunteers first to see how it works in the body and if it's safe, without other health problems making it unclear.

Will this study cure my arthritis?

No, this study is for healthy men and is not designed to treat existing conditions. Its purpose is to gather basic information about the new medicine.

How long will I need to be in the study?

The exact duration would be explained before you join, but early-stage studies often involve multiple visits over weeks or a few months.

Will I get paid for taking part?

Some studies offer payment for your time and travel, but this is something you would need to ask the study team directly.